PURPOSE: Researchers have hypothesized that an imbalance of immune cells in the uterine decidua and a dysfunction in cytokines they produce may contribute to recurrent pregnancy loss (RPL). The objective of this study was to determine if IL-22, IL-23 and IL-17 are expressed abnormally in the decidua of patients with RPL compared to those women with a normal pregnancy. We also sought to confirm that uterine natural killer (uNK) cells are lower in the decidua of patients with RPL, as well as identify IL-22 expression by uNK cells. METHODS: After meeting strict inclusion criteria, maternal decidua of nine patients with unexplained RPL and a confirmed euploid fetal loss, and 11 gestational age-matched patients undergoing elective pregnancy termination were included in our analysis. Quantitative real time-polymerase chain reaction (qRT-PCR) was performed to quantify RNA expression, Western blot was performed to quantify protein expression and immunohistochemistry (IHC) was performed to identify IL-22 and uNK cells. RESULTS: We found that women with unexplained RPL and a euploid fetal loss had significantly less gene and protein expression of IL-22 in the decidua. Additionally, we found that IL-22 is primarily expressed by uNK cells in the decidua. CONCLUSIONS: In conclusion, our results suggest that lower levels of IL-22 in the uterine decidua in patients with unexplained RPL may contribute to a disruption of decidual homeostasis and ultimately lead to early pregnancy loss.
PURPOSE: Researchers have hypothesized that an imbalance of immune cells in the uterine decidua and a dysfunction in cytokines they produce may contribute to recurrent pregnancy loss (RPL). The objective of this study was to determine if IL-22, IL-23 and IL-17 are expressed abnormally in the decidua of patients with RPL compared to those women with a normal pregnancy. We also sought to confirm that uterine natural killer (uNK) cells are lower in the decidua of patients with RPL, as well as identify IL-22 expression by uNK cells. METHODS: After meeting strict inclusion criteria, maternal decidua of nine patients with unexplained RPL and a confirmed euploid fetal loss, and 11 gestational age-matched patients undergoing elective pregnancy termination were included in our analysis. Quantitative real time-polymerase chain reaction (qRT-PCR) was performed to quantify RNA expression, Western blot was performed to quantify protein expression and immunohistochemistry (IHC) was performed to identify IL-22 and uNK cells. RESULTS: We found that women with unexplained RPL and a euploid fetal loss had significantly less gene and protein expression of IL-22 in the decidua. Additionally, we found that IL-22 is primarily expressed by uNK cells in the decidua. CONCLUSIONS: In conclusion, our results suggest that lower levels of IL-22 in the uterine decidua in patients with unexplained RPL may contribute to a disruption of decidual homeostasis and ultimately lead to early pregnancy loss.
Authors: Victoria Male; Tiffany Hughes; Susan McClory; Francesco Colucci; Michael A Caligiuri; Ashley Moffett Journal: J Immunol Date: 2010-08-27 Impact factor: 5.422
Authors: Lauren A Zenewicz; George D Yancopoulos; David M Valenzuela; Andrew J Murphy; Sean Stevens; Richard A Flavell Journal: Immunity Date: 2008-12-19 Impact factor: 31.745
Authors: Marina Cella; Anja Fuchs; William Vermi; Fabio Facchetti; Karel Otero; Jochen K M Lennerz; Jason M Doherty; Jason C Mills; Marco Colonna Journal: Nature Date: 2008-11-02 Impact factor: 49.962
Authors: Karen C Wheeler; Manoj K Jena; Bhola S Pradhan; Neha Nayak; Subhendu Das; Chaur-Dong Hsu; David S Wheeler; Kang Chen; Nihar R Nayak Journal: PLoS One Date: 2018-01-11 Impact factor: 3.240
Authors: Nicoletta Di Simone; Fiorella Di Nicuolo; Riccardo Marana; Roberta Castellani; Francesco Ria; Manuela Veglia; Giovanni Scambia; Daniel Surbek; Eytan Barnea; Martin Mueller Journal: PLoS One Date: 2017-07-12 Impact factor: 3.240
Authors: João Mendes; Paulo Rodrigues-Santos; Ana Luísa Areia; Jani-Sofia Almeida; Vera Alves; Manuel Santos-Rosa; Anabela Mota-Pinto Journal: BMC Immunol Date: 2021-05-06 Impact factor: 3.615